Influence of Glutargin on Functional State of the Liver in Patients with Chronic Heart Failure


chronic heart failure
liver function

How to Cite

Virstiuk, N. G., & Cherkashyna, O. Y. (2015). Influence of Glutargin on Functional State of the Liver in Patients with Chronic Heart Failure. Galician Medical Journal, 22(4), 68-71. Retrieved from


104 patients (60 males and 54 females) with stage II-III arterial hypertension (AH) and chronic heart failure (CHF) were examined to study the effects of complex treatment with glutargin on the functional state of the liver in patients with CHF. Among patients there were 45 patients with stage IIA CHF NYHA FC III and 59 patients with stage IIB CHF NYHA FC IV. All the patients were divided depending on treatment: Group IA included 33 patients with AH complicated by stage IIA CHF; Group IIA included 12 patients with AH and stage IIB CHF who received basic therapy. Groups IA and IIA were the comparison groups. Group IB consisted of 39 patients with AH and stage IIA CHF, and Group IIB consisted of 20 patients with AH and stage IIB CHF, who, in addition to basic therapy, received arginine glutamate. The control group included 20 practically healthy persons. Standard clinical, ultrasound and biochemical investigations were performed. The results revealed that the inclusion of glutargin in treatment of patients with AH and CHF improves overall liver function reducing the degree of cytolytic and cholestatic syndromes and improving detoxification and protein-synthesizing functions of hepatocytes.



Voronkov LH. Life expectancy for patients with chronic heart failure: as long as possible, as comfortable as possible. Sertseva nedostatnist. 2014;1:7-10.

Zharinova VYu. Modern possibilities of optimization of treatment strategies for endotheliopathy in patients with CHF (focus on eNOS). Sertseva nedostatnist. 2013;3:45-53.

Voronkov LH, Amosova KM, Bahrii AE, et al. Guidelines for the diagnosis and treatment of chronic heart failure (2012). Sertseva nedostatnist. 2012;3:60-96.

Ryabenko DV. Pharmacotherapy of chronic heart failure in the XXI century: achievements and questions. Sertseva nedostatnist. 2014;2:24-33.

Lee WJ, Ou HC, Hsu WC, et al. Ellagic acid inhibits oxidized LDL-mediated LOX-1 expression, ROS generation, and inflammation in human endothelial cells. J. Vasc. Surg. 2010;52:1290-1300.

Rochette L, Tatou E, Maupoil V, et al. Atrial and vascular oxidative stress in patients with heart failure. Cell Physiol. Biochem. 2011;27:497-502.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.